Olympus (TSE:7733) ROCE %: 10.23% (As of Mar. 2026)

What is Olympus ROCE %?

Olympus TSE:7733 +2.97% 82 ROCE % is 10.23% as of Mar. 2026. GuruFocus rates TSE:7733 with a GF Score™ of 82/100 and a GF Value™ of 円2,593.47 (Significantly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Olympus's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.23%.

Olympus (TSE:7733) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Olympus ROCE % Related Terms

Olympus ROCE % Historical Data

* Premium members only.

The historical data trend for Olympus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olympus ROCE % Chart

Olympus Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

16.06

18.78

5.02

15.72

9.80

Olympus Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															21.76	6.88	12.18	9.12	10.23

82GF Score

Olympus Corp TSE:7733

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Olympus ROCE % Calculation

Olympus's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	103291	/	( ( (1433273 - 425366)	+	(1537162 - 436874) )	/ 2 )
	=	103291	/	( (1007907	+	1100288)	/ 2 )
	=	103291	/	1054097.5
	=	9.80 %

Olympus's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	110376	/	( ( (1457917 - 400733)	+	(1537162 - 436874) )	/ 2 )
	=	110376	/	( ( 1057184	+	1100288 )	/ 2 )
	=	110376	/	1078736
	=	10.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 10.23% mean?

Olympus (TSE:7733) has a ROCE % of 10.23% as of Mar. 2026.

Is Olympus' ROCE % too high?

Olympus' current ROCE % is 10.23%. The Medical Devices & Instruments industry median ROCE % is 2.23. Olympus' value of 10.23% is 358.7% above this industry median. Overall, Olympus has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Olympus' ROCE % compare to ABT and SYK?

Olympus' ROCE % of 10.23% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Olympus' value of 10.23% is 358.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olympus's current ROCE % of 10.23% is 358.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olympus's current ROCE % is 10.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Olympus stock overvalued right now?

Based on GuruFocus' analysis, Olympus (TSE:7733) is currently considered Significantly Undervalued. The stock's GF Value™ is 円2,593.47, compared to a current price of 円1,684.00 — trading 35.1% below its estimated fair value. The current ROCE % is 10.23% and 358.7% above the Medical Devices & Instruments industry median of 2.23. Olympus' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Olympus (TSE:7733), the current ROCE % is 10.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Olympus (TSE:7733) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of 円1,684.00 is trading 35.1% below its estimated GF Value™ of 円2,593.47. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for TSE:7733:

ROCE %: 10.23%
GF Value™: 円2,593.47 vs. price of 円1,684.00 (35.1% below fair value)
GF Score™: 82/100 with 3 warning signs
Industry Position: 358.7% above the Medical Devices & Instruments median

No single metric tells the full story. See the TSE:7733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Olympus Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TSE:6869 TSE:6960 TSE:6849 TSE:6523 TSE:4549 TSE:7575 TSE:7779 TSE:7777 TSE:6823 TSE:4548 ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges OLYMY:USA OCPNF:USA OLY1:Germany

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507

Website https://www.olympus.co.jp

Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.

82GF Score

Get the complete analysis for TSE:7733

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,684.00

Price

円2,593.47

GF Value

View TSE:7733 Analysis

See ROCE % data for all stocks →